IDEAL_ANSWER:
- Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R.

EXACT_ANSWER:
- In ALK-positive NSCLC